NO996274L - CD154-blokkering for terapeutisk protein-inhibitorsyndrom - Google Patents
CD154-blokkering for terapeutisk protein-inhibitorsyndromInfo
- Publication number
- NO996274L NO996274L NO996274A NO996274A NO996274L NO 996274 L NO996274 L NO 996274L NO 996274 A NO996274 A NO 996274A NO 996274 A NO996274 A NO 996274A NO 996274 L NO996274 L NO 996274L
- Authority
- NO
- Norway
- Prior art keywords
- blockage
- protein inhibitor
- therapeutic protein
- exogenous protein
- inhibitor syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5027697P | 1997-06-20 | 1997-06-20 | |
PCT/US1998/012773 WO1998058672A1 (en) | 1997-06-20 | 1998-06-19 | Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
NO996274D0 NO996274D0 (no) | 1999-12-17 |
NO996274L true NO996274L (no) | 2000-02-18 |
Family
ID=21964347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO996274A NO996274L (no) | 1997-06-20 | 1999-12-17 | CD154-blokkering for terapeutisk protein-inhibitorsyndrom |
Country Status (25)
Country | Link |
---|---|
US (1) | US20020119151A1 (no) |
EP (1) | EP1034001B1 (no) |
JP (1) | JP2002504910A (no) |
KR (1) | KR100567998B1 (no) |
CN (2) | CN1651071A (no) |
AT (1) | ATE272408T1 (no) |
AU (1) | AU733062B2 (no) |
BG (1) | BG64436B1 (no) |
BR (1) | BR9810755A (no) |
CA (1) | CA2294138A1 (no) |
CZ (1) | CZ295805B6 (no) |
DE (1) | DE69825473T2 (no) |
EA (1) | EA002512B1 (no) |
EE (1) | EE9900587A (no) |
ES (1) | ES2226152T3 (no) |
HK (1) | HK1031825A1 (no) |
HU (1) | HUP0002048A3 (no) |
IL (1) | IL133305A0 (no) |
IS (1) | IS2097B (no) |
NO (1) | NO996274L (no) |
NZ (1) | NZ502051A (no) |
PT (1) | PT1034001E (no) |
SK (1) | SK285962B6 (no) |
TR (1) | TR199903141T2 (no) |
WO (1) | WO1998058672A1 (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2343916A1 (en) * | 1998-09-21 | 2000-03-30 | Genetics Institute, Inc. | Methods of downmodulating the immune response to therapeutic proteins |
WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
CA2408691A1 (en) | 2000-05-12 | 2001-11-22 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
IES20030298A2 (en) * | 2002-04-23 | 2003-10-29 | R Stephen Porter | Inhibition of platelet aggregation |
AU2011224032B2 (en) * | 2003-06-13 | 2013-01-31 | Biogen Ma Inc. | Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof |
ES2353222T3 (es) * | 2003-06-13 | 2011-02-28 | Biogen Idec Ma Inc. | Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos. |
KR20120090094A (ko) * | 2003-06-13 | 2012-08-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아글리코실 항-cd154(cd40 리간드) 항체 및 이의 용도 |
PT1682180E (pt) | 2003-11-04 | 2010-02-10 | Novartis Vaccines & Diagnostic | Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização |
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | ANTI-CD154 ANTIBODIES |
US20070286855A1 (en) * | 2004-08-03 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Improving treatments |
PL1889065T3 (pl) | 2005-05-18 | 2013-12-31 | Novartis Ag | Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny |
SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
US9447156B2 (en) | 2011-05-17 | 2016-09-20 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
IL130785A0 (en) * | 1997-01-10 | 2001-01-28 | Biogen Inc | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same |
-
1998
- 1998-06-19 JP JP50339199A patent/JP2002504910A/ja not_active Ceased
- 1998-06-19 EE EEP199900587A patent/EE9900587A/xx unknown
- 1998-06-19 CN CNA2004100978650A patent/CN1651071A/zh active Pending
- 1998-06-19 KR KR1019997011990A patent/KR100567998B1/ko not_active IP Right Cessation
- 1998-06-19 AT AT98931391T patent/ATE272408T1/de not_active IP Right Cessation
- 1998-06-19 ES ES98931391T patent/ES2226152T3/es not_active Expired - Lifetime
- 1998-06-19 AU AU81536/98A patent/AU733062B2/en not_active Ceased
- 1998-06-19 DE DE69825473T patent/DE69825473T2/de not_active Expired - Fee Related
- 1998-06-19 HU HU0002048A patent/HUP0002048A3/hu unknown
- 1998-06-19 EA EA200000059A patent/EA002512B1/ru not_active IP Right Cessation
- 1998-06-19 PT PT98931391T patent/PT1034001E/pt unknown
- 1998-06-19 WO PCT/US1998/012773 patent/WO1998058672A1/en active IP Right Grant
- 1998-06-19 CN CN98806403A patent/CN1261285A/zh active Pending
- 1998-06-19 CZ CZ19994588A patent/CZ295805B6/cs not_active IP Right Cessation
- 1998-06-19 TR TR1999/03141T patent/TR199903141T2/xx unknown
- 1998-06-19 CA CA002294138A patent/CA2294138A1/en not_active Abandoned
- 1998-06-19 SK SK1803-99A patent/SK285962B6/sk unknown
- 1998-06-19 EP EP98931391A patent/EP1034001B1/en not_active Expired - Lifetime
- 1998-06-19 BR BR9810755-0A patent/BR9810755A/pt not_active Application Discontinuation
- 1998-06-19 NZ NZ502051A patent/NZ502051A/en unknown
- 1998-06-19 IL IL13330598A patent/IL133305A0/xx unknown
-
1999
- 1999-11-26 IS IS5274A patent/IS2097B/is unknown
- 1999-12-17 NO NO996274A patent/NO996274L/no not_active Application Discontinuation
-
2000
- 2000-01-18 BG BG104092A patent/BG64436B1/bg unknown
-
2001
- 2001-02-14 HK HK01101074A patent/HK1031825A1/xx not_active IP Right Cessation
-
2002
- 2002-04-19 US US10/127,228 patent/US20020119151A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO996274L (no) | CD154-blokkering for terapeutisk protein-inhibitorsyndrom | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
NO20016007L (no) | Rekombinant anti-CD40-antistoff og anvendelser derav | |
WO2001024816A3 (en) | Compositions and methods relating to the inhibition of casomorphin and gluteomorphin | |
FI925615A (fi) | Stabiliserade farmaceutiska kompositioner, som innehaoller en HMG-CoA-reduktas-inhibitorfoerening | |
UA66767C2 (uk) | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с | |
MXPA03002477A (es) | N-acilsulfonamidas promotras de la apoptosis. | |
AU2002360592A1 (en) | Inhibitors of hepatitis c virus | |
FI953748A (fi) | Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina | |
BR9811099A (pt) | Inibidores de urocinase | |
ATE170868T1 (de) | Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen | |
DK641589D0 (da) | N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer | |
DK0606248T3 (da) | Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer | |
EA200100732A1 (ru) | Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию | |
AU3864000A (en) | Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses | |
WO2000041508A3 (en) | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines | |
DK0584247T3 (da) | Sammensætninger til behandling af kronisk træthedssyndrom | |
HK1045456A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
FI962264A0 (fi) | Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana | |
WO2003099212A3 (en) | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy | |
AU2000265105A1 (en) | Methods and compositions for the prevention and treatment of syndrome x | |
UA94022C2 (ru) | Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита | |
NO20001846D0 (no) | Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer | |
WO1998018818A3 (en) | Hepatitis b inhibitors | |
WO2004017902A3 (en) | Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |